Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Rent the Runway Inc (RENT) Price & Performance

Adaptive Biotechnologies Corp
Rent the Runway Inc

Price performance

Price movement over the last 24 hours

Key statistics

Adaptive Biotechnologies Corp vs Rent the Runway Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Rent the Runway Inc trades at $3.4 (market cap $115.40M). The key difference: Adaptive Biotechnologies Corp is far larger — about 28.9× Rent the Runway Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals.

ADPTRENT
Market Cap
$3.33B$115.40M
Sector
HealthConsumer Cyclical
52-Week High
$22.37$9.39
52-Week Low
$10.24$3.10
Enterprise Value
$3.19B$275.50M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Rent the Runway Inc

RENT trades at $3.42, down 0.87% on the day, with a bearish technical signal. The company reported Q1 2026 revenue of $89.9 million, up 29.2% year-over-year, but continues to post net losses. Valuation ratios appear low with a P/E of 0.43 and P/S of 0.18, while negative equity of -$182.5 million and high debt levels pose financial risks. Recent leadership changes include the appointment of an interim CEO.

The outlook is mixed: strong revenue growth and low valuations suggest potential upside, but persistent losses, negative equity, and high leverage present significant risks. Analyst consensus is divided with 42% buy ratings, though no sell ratings exist. The stock's direction hinges on achieving profitability and managing debt.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Rent the Runway Inc

Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.

Read more on RENT